Esperion’s cholesterol drug clears the last big safety hurdle, turning the corner to the FDA — now the big challenge looms
Esperion $ESPR looks set to make the final step in its long journey toward a marketing application at the FDA, with good odds of success …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
